For most people, a falling temperature is a reassuring sign that an illness is coming to an end. With dengue fever, however, that assumption can be dangerous. Some patients enter the most critical stage of the infection just as their fever subsides, potentially developing internal bleeding, circulatory shock or organ damage within hours.
The disease, sometimes called "breakbone fever" because of the intense pain it can cause, has become one of the world's most significant mosquito-borne viral infections. According to the World Health Organization's global update published on October 9, 2026, approximately 2.2 million dengue cases and more than 1,100 associated deaths were reported across 97 countries, territories and areas between January and August 2026.
Although those numbers represent a substantial decline from the corresponding periods in 2024 and 2025, dengue remains a serious public health challenge. Outbreaks are affecting parts of Asia, Latin America, Africa and the Pacific, while locally acquired infections in European countries demonstrate that the disease is no longer exclusively a concern for tropical destinations.
How do people become infected with dengue fever?
Dengue is caused by a virus transmitted primarily through the bite of an infected female mosquito. The two principal carriers are Aedes aegypti, commonly known as the yellow fever mosquito, and Aedes albopictus, often called the Asian tiger mosquito. Both species are capable of living close to humans, making densely populated urban neighbourhoods particularly suitable environments for transmission.
Also read: Daily vitamin C cut deaths nearly in half in a randomized blood cancer trial
Unlike mosquitoes that primarily bite at night, these species are frequently active during daylight hours, particularly in the early morning and late afternoon. They can also bite at night. According to the US Centers for Disease Control and Prevention, the mosquitoes commonly reproduce in containers holding water, including flowerpots, buckets, discarded tyres and water-storage containers.
The transmission cycle begins when a mosquito bites someone carrying dengue virus in their blood. After the virus develops inside the mosquito, it can be transmitted to another person through a subsequent bite. Dengue is not ordinarily spread through coughing, hugging, sharing food or other everyday contact between people.
Rare transmission can occur through infected blood, organ transplantation or certain healthcare exposures. The virus may also pass from a pregnant woman to her baby during pregnancy or around childbirth, although mosquito bites remain overwhelmingly the principal route of infection.
Why getting dengue once does not necessarily protect you
One unusual feature of dengue is that recovering from the disease does not guarantee immunity against future infections. Four established dengue virus types circulate internationally, designated DENV-1, DENV-2, DENV-3 and DENV-4. Infection generally provides long-lasting protection against the particular type responsible, but protection against the other types is limited.
Also read: Half a million heart deaths a year come down to one number most people never check
This means that a person can contract dengue several times during their lifetime. More importantly, a subsequent infection with a different virus type can increase the risk of developing severe dengue. Scientists associate part of this increased risk with a process called antibody-dependent enhancement, in which certain antibodies from an earlier infection can facilitate infection of immune cells during a later infection.
That does not mean everyone infected for a second time will become seriously ill. Most dengue infections remain mild or produce no noticeable symptoms. Nevertheless, previous infection is an important consideration when doctors evaluate patients, particularly in countries where several dengue virus types circulate simultaneously.
Which countries are most affected by dengue?
Dengue is established across much of the tropical and subtropical world, but its geographical distribution is changing. The Americas, South Asia and the Western Pacific account for substantial numbers of reported infections, while parts of Africa and the Middle East are experiencing significant outbreaks and changes in transmission patterns.
Brazil has reported the largest number of dengue cases globally in 2026. According to WHO surveillance covering January through August, the country recorded more than 1.2 million suspected and confirmed cases combined. Other countries reporting substantial numbers included Vietnam, with approximately 106,800 cases, and Sri Lanka, with approximately 95,500.
Also read: FDA clears a drug that lets some rectal cancer patients skip surgery entirely
Across Latin America, dengue is also a persistent problem in countries such as Colombia, Mexico, Peru and Bolivia. Caribbean countries and territories experience outbreaks as well. On October 20, 2026, the Pan American Health Organization issued an epidemiological update warning of increasing activity in parts of the Andean, Central American and Caribbean subregions ahead of the approaching seasonal peak in South America.
In Asia, dengue affects countries including India, Bangladesh, Thailand, Indonesia, Cambodia, Malaysia and the Philippines. Notably, WHO recorded higher case totals during the first eight months of 2026 than during the corresponding periods of both 2024 and 2025 in countries including Sri Lanka, Cambodia and Vietnam. Countries experiencing significant increases elsewhere included Sudan, Kenya and Iran.
The Pacific islands also face considerable risks. In smaller populations, even outbreaks involving a few thousand infections can produce extremely high infection rates relative to population size. WHO identified the Cook Islands, Guyana and Samoa among the territories and countries with particularly high reported dengue incidence during the first eight months of 2026.
Dengue is also appearing in Europe
For many years, dengue was regarded primarily as an infection associated with international travel. European patients were usually people who had visited tropical or subtropical destinations and returned home carrying the virus. While imported infections remain important, locally acquired cases have increasingly attracted the attention of European health authorities.
Also read: One reading during your sleep study could flag your heart failure risk a decade early
According to the European Centre for Disease Prevention and Control's weekly surveillance report, Italy had recorded 70 locally acquired dengue cases in 2026 as of October 14, while France had recorded six. These are infections acquired through local transmission rather than simply diagnosed after someone returned from abroad.
The changing distribution of mosquitoes helps explain the concern. The Asian tiger mosquito is established in parts of 16 European Union and European Economic Area countries, including Italy, France, Spain, Germany, Greece, Croatia and Portugal. Its presence alone does not mean dengue is circulating locally, but it creates the possibility of transmission when an infected traveller enters an area where suitable mosquitoes are active.
Northern European countries generally face a much lower risk of locally acquired dengue than tropical regions. Nevertheless, changing climatic conditions and international travel mean public health authorities must monitor mosquito populations and imported infections carefully.
Why is dengue spreading into new regions?
Several overlapping factors influence the distribution of dengue. Higher temperatures can create more favourable conditions for mosquito activity and viral development, while rainfall and water storage practices can increase the number of breeding sites. In densely populated cities, mosquitoes may encounter large numbers of potential human hosts within relatively small areas.
Also read: Being lonely could cost you nearly 6 years free from depression and anxiety
Climate change is one contributor, but it is not the only explanation. Urban expansion, population growth, inadequate mosquito control and international movement of people and goods also influence where dengue can circulate. The virus can be introduced into an area by an infected traveller, but sustained transmission requires suitable mosquito populations and environmental conditions.
Global trends also need to be interpreted carefully. The latest WHO figures show that reported dengue cases were lower worldwide during January–August 2026 than in the same periods of 2024 and 2025. However, 27 countries, territories and areas reported higher case totals during that period than in either of the preceding two years, demonstrating how local outbreaks can intensify even when global figures decline.
Who is most likely to become seriously ill?
Anyone bitten by an infected mosquito can develop dengue, regardless of age, sex or general fitness. The risk of becoming infected depends primarily on exposure to mosquitoes carrying the virus. People living in areas with sustained transmission, particularly densely populated communities with inadequate mosquito protection, face repeated opportunities for infection.
The risk of complications is not distributed equally. The ECDC's clinical factsheet on dengue identifies infancy, older age, previous dengue infection and certain underlying health conditions among the factors associated with a higher likelihood of severe disease. These conditions include diabetes, asthma, hypertension and kidney disease.
Pregnant women also require particular medical attention because dengue can increase the risk of complications affecting both mother and baby. People with chronic liver disease, immune-related vulnerabilities or conditions affecting their ability to tolerate fluid loss may also need closer monitoring. Healthcare access matters considerably, since recognising deterioration quickly and providing appropriate treatment can substantially reduce the risk of death.
For travellers, risk is not limited to prolonged stays or rural destinations. Dengue-transmitting mosquitoes are well adapted to cities and residential environments, so people visiting urban centres, hotels and tourist areas can also be exposed.
What are the first symptoms of dengue fever?
Dengue symptoms generally begin between four and ten days after an infected mosquito bite. The illness can initially resemble influenza or another common viral infection, which can make early identification difficult without information about recent travel or local mosquito-borne disease activity.
Typical symptoms include sudden high fever, sometimes approaching 40°C, severe headaches, pain behind the eyes, intense muscle and joint pain, nausea, vomiting, fatigue and a skin rash. Some patients develop swollen glands or minor bleeding, such as bleeding from the gums or nose.
Despite its alarming reputation, most dengue infections do not cause severe illness. According to the CDC's clinical overview updated in February 2026, approximately one in four people infected with dengue develop symptoms. Most symptomatic patients improve within one or two weeks, although fatigue and weakness can continue beyond the initial illness.
The symptoms usually persist for two to seven days. During this period, people may experience considerable discomfort, reduced appetite and dehydration. However, the end of the fever does not always mean the most dangerous period has passed.
The most dangerous stage can begin when the fever disappears
One of the most important features of dengue is its potential progression into a critical phase around the time the fever begins to subside. In patients who develop severe disease, changes in blood vessel permeability can allow fluid to leak out of the bloodstream into surrounding tissues and body cavities.
This fluid leakage can cause a dangerous fall in circulating blood volume and blood pressure. Severe cases may progress to shock, breathing difficulties, significant bleeding or damage affecting organs such as the liver, heart and brain. These complications can develop rapidly, making close observation particularly important when warning signs emerge.
Warning signs include severe or persistent abdominal pain, repeated vomiting, bleeding from the nose or gums, blood in vomit or stool, unusual drowsiness, restlessness, rapid breathing and cold or clammy skin. The critical period often develops around the time the fever breaks and may last approximately 24 to 48 hours.
Anyone experiencing these symptoms after possible dengue exposure should seek urgent medical attention, even if their temperature has returned to normal. Severe dengue is a medical emergency, and delaying treatment can have life-threatening consequences.
How do doctors diagnose dengue?
A dengue diagnosis cannot reliably be established from symptoms alone. Fever, headache, muscle pain and rash can also occur with other infections, including malaria, chikungunya and Zika. Doctors therefore consider recent travel, local outbreak conditions, medical history and the timing of symptoms before selecting appropriate tests.
During the first seven days of illness, blood tests can identify dengue virus genetic material through molecular testing, such as PCR, or detect the viral NS1 antigen. Antibody tests, particularly those measuring IgM, become more useful as the infection progresses. According to the CDC's diagnostic guidance, suspected dengue should receive appropriate clinical management without waiting for test results.
Blood tests may also help doctors monitor platelet levels, blood concentration and signs of organ involvement. These measurements can be especially important in patients who develop warning signs or require hospital treatment.
Is there a cure for dengue fever?
There is currently no specific antiviral medicine routinely available to cure dengue. Treatment focuses on controlling symptoms, maintaining hydration and preventing complications while the body's immune system responds to the infection.
For mild cases, doctors generally recommend rest, adequate fluid intake and paracetamol, known as acetaminophen in the United States, to relieve fever and pain. Oral rehydration solutions may be useful when patients are struggling to replace fluids lost through fever or vomiting.
An important precaution is to avoid aspirin, ibuprofen and other non-steroidal anti-inflammatory medicines unless a clinician has specifically advised otherwise after assessing the situation. These medications can increase the risk of bleeding in patients with dengue.
Patients who develop warning signs may require hospital admission. According to the CDC's clinical treatment recommendations updated in April 2026, hospital management may involve carefully controlled intravenous fluids, frequent assessment of blood pressure and circulation, and monitoring of blood tests and urine output.
In severe cases, emergency treatment aims to restore and maintain circulation while avoiding excessive fluid administration. Significant bleeding may require blood transfusion, although routine preventive platelet transfusions are not recommended. Intensive care can be necessary for patients experiencing shock, severe haemorrhage or organ failure.
How deadly is dengue fever?
Dengue can be fatal, but most people who become infected survive, and many never experience symptoms. The likelihood of death varies substantially depending on disease severity, underlying medical conditions, previous infections and access to timely healthcare.
The CDC estimates that approximately one in twenty patients with symptomatic dengue may develop severe, potentially life-threatening disease. However, severe illness does not automatically result in death. Prompt recognition and appropriate supportive treatment can reduce the risk of fatal outcomes dramatically.
The ECDC reports that the overall case-fatality rate among reported dengue patients is generally below one percent, although this figure varies between countries and surveillance systems. With effective clinical management, dengue case fatality can be kept below 0.5 percent in well-managed settings. These percentages should not be interpreted as a universal individual risk because mild infections are frequently missed and reporting practices differ substantially.
The scale of dengue nevertheless creates a considerable public health burden. WHO received reports of more than 1,100 dengue-associated deaths globally during the first eight months of 2026. The actual number of infections is considerably greater than the number officially recorded, partly because many people never develop symptoms or seek testing.
Can you get vaccinated against dengue?
Vaccines are available in some countries, although dengue vaccination is more complicated than vaccination against many other infectious diseases. The existence of four virus types, together with differences in immunity between people who have and have not previously been infected, makes vaccine selection and public health recommendations particularly important.
One vaccine, Qdenga, developed by Takeda, has been authorised in numerous countries, including in the European Union. It is administered in two doses separated by three months. Although the vaccine is authorised in the EU for people aged four years and older, eligibility for vaccination depends on national recommendations and individual circumstances.
The WHO's dengue vaccination recommendations focus on children aged six to sixteen living in settings where dengue transmission is particularly intense. Travellers may also be considered for vaccination in certain countries, but recommendations often depend on whether they have previously been infected.
Another vaccine, Dengvaxia, was previously used for selected children with laboratory-confirmed prior dengue infection, but its manufacturer discontinued the product. In Brazil, a newer single-dose vaccine called Butantan-DV was authorised in late 2025, although its use was temporarily suspended in June 2026 while reports of possible adverse events were investigated.
According to the CDC's September 2026 vaccine update, no dengue vaccines were available in the United States at that time. Vaccine availability therefore differs considerably between countries. People considering vaccination should consult a qualified travel medicine specialist or healthcare professional, particularly if they are pregnant, immunocompromised or uncertain whether they have previously had dengue.
How can you protect yourself against dengue?
Avoiding mosquito bites remains the most broadly applicable method of preventing dengue. This is important not only for people living in areas where the virus regularly circulates, but also for travellers visiting affected countries and communities experiencing local outbreaks.
Health authorities recommend using effective mosquito repellents containing ingredients such as DEET or picaridin, wearing clothing that covers the arms and legs, and staying in accommodation with effective window screens or air conditioning. Mosquito nets can provide additional protection, particularly when resting or sleeping in accommodation where mosquitoes can enter.
Reducing mosquito breeding sites is equally important. Water should not be allowed to accumulate unnecessarily in containers, flowerpots, buckets or discarded objects around homes and residential buildings. Community mosquito-control programmes can help reduce transmission, particularly in densely populated neighbourhoods.
People who develop dengue should also protect themselves from further mosquito bites while the virus may still be present in their blood. Otherwise, an uninfected mosquito could acquire the virus and subsequently transmit it to someone else.
The CDC's dengue prevention advice also recommends that travellers returning from areas where dengue circulates take precautions against mosquito bites for three weeks, even if they do not feel ill. This can help reduce the possibility of introducing the virus into mosquito populations capable of spreading it locally.
Why dengue deserves attention even as global cases decline
Dengue illustrates how a disease can remain a major health threat without case numbers increasing everywhere at the same time. Global reports for 2026 indicate a decline from the extraordinary outbreaks recorded in 2024, but significant transmission continues across multiple continents, and some countries are experiencing unusually large outbreaks.
As climate conditions, mosquito populations, urban environments and international travel patterns continue to change, the geographical boundaries of dengue transmission may also shift. The occurrence of locally acquired infections in parts of Europe underlines the importance of surveillance beyond countries where dengue has traditionally been widespread.
For individuals, however, the most important message remains straightforward. Most people recover from dengue, but recognising the warning signs of severe disease can save lives. In particular, a disappearing fever should never be treated as proof of recovery when abdominal pain, repeated vomiting, bleeding or other signs of deterioration are developing.
This article is made and published by Aksel Kryhlmand, who may have used AI in the preparation.